Drug Trial Radar · NCT06374394
A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above
Last checked: Nov 20, 2026Latest source record: Dec 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
841
Actual
Start
Apr 29, 2024
Primary completion
Nov 1, 2024
Study completion Mar 31, 2025
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Apr 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is assessing the immunogenicity, safety and reactogenicity of the RSVPreF3 OA investigational vaccine when it is co-administered with a COVID-19 messenger ribonucleic acid (mRNA) vaccine (Omicron XBB.1.5), compared to administration of the vaccines separately in adults aged 50 years and above.
Conditions
- Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 OA investigational vaccineBiological
1 dose of RSVPreF3 OA investigational vaccine is administered intramuscularly on Day 1 to participants in the Co-ad Group and on Day 31 to participants in the Control Group.
COVID-19 mRNA vaccineBiological
1 dose of COVID-19 mRNA vaccine is administered intramuscularly on Day 1 to participants in the Co-ad and Control Groups.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adjusted Geometric Mean Titers (GMT) of Respiratory Syncytial Virus-A (RSV-A) Neutralizing Titers at 1 Month After the RSVPreF3 OA VaccinationTime frame: At 1 month post-RSVPreF3 OA vaccine dose administration (at Day 31 for Co-Ad Group and Day 61 for Control Group)
- Adjusted GMTs of RSV-B Neutralizing Titers at 1 Month After the RSVPreF3 OA VaccinationTime frame: At 1 month post-RSVPreF3 OA vaccine dose administration (at Day 31 for Co-Ad Group and Day 61 for Control Group)
- Adjusted GMTs of SARS-CoV-2 Omicron XBB.1.5 Neutralizing Titers at 1 Month After the COVID-19 mRNA VaccinationTime frame: At 1 month post-COVID-19 mRNA vaccine dose administration (at Day 31 for both groups)
Locations
24 sites in 4 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Coral Gables, Florida
GSK Investigational Site
Savannah, Georgia
GSK Investigational Site
Evansville, Indiana
GSK Investigational Site
Omaha, Nebraska
GSK Investigational Site
Rochester, New York
GSK Investigational Site
Winston-Salem, North Carolina
GSK Investigational Site
North Charleston, South Carolina
GSK Investigational Site
Newport News, Virginia
GSK Investigational Site
Antwerp, Belgium
GSK Investigational Site
Edegem, Belgium
GSK Investigational Site
Ghent, Belgium
GSK Investigational Site
Kluisbergen, Belgium
GSK Investigational Site
Mechelen, Belgium
GSK Investigational Site
Breda, Netherlands
GSK Investigational Site
Enschede, Netherlands
GSK Investigational Site
Utrecht, Netherlands
GSK Investigational Site
Zutphen, Netherlands
GSK Investigational Site
A Coruña, Spain
GSK Investigational Site
Barcelona, Spain
GSK Investigational Site
Barcelona, Spain
GSK Investigational Site
Boadilla Del Monte Madrid, Spain
GSK Investigational Site
Madrid, Spain
GSK Investigational Site
Madrid, Spain
GSK Investigational Site
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.